Pfizer has just made venture capital firm Flagship Pioneering a key component of its R&D engine, signing a deal worth up to $7 billion that will allow it to harvest ne
Sanofi’s plan to become a dominant player in the respiratory syncytial virus (RSV) market has moved a step closer, with FDA approval of Beyfortus for the prevention of RSV
BridgeBio is getting ready to file for FDA approval of its acoramidis drug for transthyretin amyloidosis (ATTR) cardiomyopathy, armed with positive results in a phase 3 tr
The US Federal Trade Commission (FTC) has asked for more information on Pfizer’s $43 billion agreement to acquire Seagen before it will deliver a decision on whether the d
South Korean contract development and manufacturing organisation (CDMO) Samsung Biologics marks another contract milestone as the company announces two high-value deals totalling £897
Sanofi is trailing behind GSK and Pfizer when it comes to vaccines for respiratory syncytial virus (RSV), but it still thinks it can be the top player in the market with a
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.